Cargando…

Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma

PURPOSE: Hepatocellular carcinoma (HCC) has a high incidence in China and exploring effective ways for early diagnosis is an important method to improve the prognosis of patients with HCC. Additional studies reported that. Some kinds of microRNA (miRNA) in plasma will change accordingly during HCC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuo, Yang, Yongxiang, Sun, Lili, Qiao, Guoliang, Song, Yunlong, Liu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069575/
https://www.ncbi.nlm.nih.gov/pubmed/32210570
http://dx.doi.org/10.2147/OTT.S232453
_version_ 1783505803985027072
author Wang, Shuo
Yang, Yongxiang
Sun, Lili
Qiao, Guoliang
Song, Yunlong
Liu, Bing
author_facet Wang, Shuo
Yang, Yongxiang
Sun, Lili
Qiao, Guoliang
Song, Yunlong
Liu, Bing
author_sort Wang, Shuo
collection PubMed
description PURPOSE: Hepatocellular carcinoma (HCC) has a high incidence in China and exploring effective ways for early diagnosis is an important method to improve the prognosis of patients with HCC. Additional studies reported that. Some kinds of microRNA (miRNA) in plasma will change accordingly during HCC progress, and this change can be used to diagnose HCC, especially with miRNA-122, miRNA-21 and miRNA-96. We were aiming at investigating the values of the exosomal miRNAs in diagnosis and prognosis for HCC patients. PATIENTS AND METHODS: Blood samples from 50 patients with HCC and 50 patients with hepatic cirrhosis and 50 healthy volunteers were obtained. The diagnostic accuracy of the plasma and exosomal miRNAs and the comparisons among different groups were measured by the area under the curve (AUC) on receiver operating characteristic (ROC) curve analysis. RESULTS: Expression levels of miRNA-21 and miRNA-96 were significantly higher in patients with HCC and of miRNA-122 were significantly lower in HCC compared with cirrhotic patients in both exosomes and plasma. Among different groups, exosomal miRNA-122, miRNA-21 and miRNA-96 were significantly more accurate in diagnosing HCC than those miRNAs in plasma and the alpha-fetoprotein (AFP) level. The miRNA panel had high accuracy in discriminating HCC from the cirrhosis group (AUC 0.924; 95% CI; sensitivity 82%, specificity 92%) and healthy volunteers’ group. Exosomal miRNA-21 and miRNA-96 with low expression and miRNA-122 with high expression could be associated with a patient’s survival time. However, the miRNA panel could better predict the HCC patient’s survival time compared with each miRNA individually. CONCLUSION: This study showed that the expression levels of miRNA-122, miRNA-21 and miRNA-96 in exosomes were more significantly changed than those miRNAs in plasma in patients with HCC compared with cirrhotic patients, and the exosomal miRNA panel containing miRNA-122, miRNA-21 and miRNA-96 could be defined as a diagnostic biomarker for patients with HCC. We also conclude that different expression of exosomal miRNAs, especially the miRNA panel, could predict the HCC patient’s prognosis.
format Online
Article
Text
id pubmed-7069575
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70695752020-03-24 Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma Wang, Shuo Yang, Yongxiang Sun, Lili Qiao, Guoliang Song, Yunlong Liu, Bing Onco Targets Ther Original Research PURPOSE: Hepatocellular carcinoma (HCC) has a high incidence in China and exploring effective ways for early diagnosis is an important method to improve the prognosis of patients with HCC. Additional studies reported that. Some kinds of microRNA (miRNA) in plasma will change accordingly during HCC progress, and this change can be used to diagnose HCC, especially with miRNA-122, miRNA-21 and miRNA-96. We were aiming at investigating the values of the exosomal miRNAs in diagnosis and prognosis for HCC patients. PATIENTS AND METHODS: Blood samples from 50 patients with HCC and 50 patients with hepatic cirrhosis and 50 healthy volunteers were obtained. The diagnostic accuracy of the plasma and exosomal miRNAs and the comparisons among different groups were measured by the area under the curve (AUC) on receiver operating characteristic (ROC) curve analysis. RESULTS: Expression levels of miRNA-21 and miRNA-96 were significantly higher in patients with HCC and of miRNA-122 were significantly lower in HCC compared with cirrhotic patients in both exosomes and plasma. Among different groups, exosomal miRNA-122, miRNA-21 and miRNA-96 were significantly more accurate in diagnosing HCC than those miRNAs in plasma and the alpha-fetoprotein (AFP) level. The miRNA panel had high accuracy in discriminating HCC from the cirrhosis group (AUC 0.924; 95% CI; sensitivity 82%, specificity 92%) and healthy volunteers’ group. Exosomal miRNA-21 and miRNA-96 with low expression and miRNA-122 with high expression could be associated with a patient’s survival time. However, the miRNA panel could better predict the HCC patient’s survival time compared with each miRNA individually. CONCLUSION: This study showed that the expression levels of miRNA-122, miRNA-21 and miRNA-96 in exosomes were more significantly changed than those miRNAs in plasma in patients with HCC compared with cirrhotic patients, and the exosomal miRNA panel containing miRNA-122, miRNA-21 and miRNA-96 could be defined as a diagnostic biomarker for patients with HCC. We also conclude that different expression of exosomal miRNAs, especially the miRNA panel, could predict the HCC patient’s prognosis. Dove 2020-03-09 /pmc/articles/PMC7069575/ /pubmed/32210570 http://dx.doi.org/10.2147/OTT.S232453 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Shuo
Yang, Yongxiang
Sun, Lili
Qiao, Guoliang
Song, Yunlong
Liu, Bing
Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma
title Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma
title_full Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma
title_fullStr Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma
title_full_unstemmed Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma
title_short Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma
title_sort exosomal micrornas as liquid biopsy biomarkers in hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069575/
https://www.ncbi.nlm.nih.gov/pubmed/32210570
http://dx.doi.org/10.2147/OTT.S232453
work_keys_str_mv AT wangshuo exosomalmicrornasasliquidbiopsybiomarkersinhepatocellularcarcinoma
AT yangyongxiang exosomalmicrornasasliquidbiopsybiomarkersinhepatocellularcarcinoma
AT sunlili exosomalmicrornasasliquidbiopsybiomarkersinhepatocellularcarcinoma
AT qiaoguoliang exosomalmicrornasasliquidbiopsybiomarkersinhepatocellularcarcinoma
AT songyunlong exosomalmicrornasasliquidbiopsybiomarkersinhepatocellularcarcinoma
AT liubing exosomalmicrornasasliquidbiopsybiomarkersinhepatocellularcarcinoma